Pure Global AI
NCT05868382Not yet recruiting

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults

A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age
ModernaTX, Inc.Phase 2ClinicalTrials.govbiological
Verified
Study focus
Disease/Condition
Influenza
Drug/Device/Intervention
mRNA-1010
Study type
Interventional
Intervention type
biological
Sponsor & location
Primary sponsor
ModernaTX, Inc.
Location
Hollywood,Miami,Lenexa,Rockville,Southfield,Hastings,Lincoln,Binghamton,Sugar Land,Tomball, United States of America
Timeline & enrollment
Phase
Phase 2
Start date
May 15, 2023
End date
Feb 15, 2024
Enrollment
270 participants
Primary outcome

Number of Participants with Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs),Number of Participants with Unsolicited Adverse Events (AEs),Number of Participants with Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESIs), Medically Attended Adverse Events (MAAEs), and AEs Leading to Discontinuation

Summary

The main purpose of the study is to evaluate the safety, reactogenicity, and the
 immunogenicity of mRNA-1010 vaccine candidate variations.

ICD-10 classifications
Influenza and pneumoniaInfluenza due to identified seasonal influenza virusInfluenza with other manifestations, seasonal influenza virus identifiedInfluenza with pneumonia, seasonal influenza virus identifiedInfluenza due to identified zoonotic or pandemic influenza virus
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05868382
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05868382 through Pure Global AI's free database. This Phase 2 trial is sponsored by ModernaTX, Inc. and is currently Not yet recruiting. The study focuses on Influenza. Target enrollment is 270 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.